{{Rsnum
|rsid=712829
|Gene=EGFR
|Chromosome=7
|position=55019062
|Orientation=plus
|GMAF=0.2562
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=EGFR
}}{{PharmGKB
|RSID=rs712829
|Name_s=EGFR:-216G>T
|Gene_s=EGFR
|Feature=5' UTR
|Evidence=PubMed ID:17375033
|Annotation=The T allele of -216G/T was associated with improved progression free survival in gefitinib-treated non-small-cell lung cancer patients. It was also associated with significantly higher rates of stable disease/partial response and a significantly higher risk of treatment-related rash/diarrhea.
|Drugs=gefitinib
|Drug Classes=
|Diseases=Carcinoma, Non-Small-Cell Lung
|Curation Level=Curated
|PharmGKB Accession ID=PA162928796
}}

{{PharmGKB
|RSID=rs712829
|Name_s=EGFR:(-)216G>T
|Gene_s=EGFR
|Feature=5' UTR
|Evidence=PubMed ID:15665278; PubMed ID:16757132; PubMed ID:16885506; PubMed ID:17192902; PubMed ID:17375033; PubMed ID:17455987
|Annotation=Increased expression in vitro and in vivo; may have clinical impact.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161145050
}}

{{PharmGKB
|RSID=rs712829
|Name_s=EGFR:-216G>T
|Gene_s=EGFR
|Feature=5' UTR
|Evidence=PubMed ID:18652519
|Annotation=NCI-60 cell lines having at least one variant T allele at the -216G>T SNP were more sensitive to erlotinib and less sensitive to geldanamycin, topoisomerase I and II inhibitors, and alkylating agents than those without a variant allele
|Drugs=erlotinib; geldanamycin
|Drug Classes=ANTINEOPLASTIC AGENTS; PODOPHYLLOTOXIN DERIVATIVES; TOPOISOMERASE I INHIBITORS
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA162372660
}}

{{PharmGKB
|RSID=rs712829
|Name_s=EGFR:-216G>T
|Gene_s=EGFR
|Feature=5' UTR
|Evidence=PubMed ID:18006781
|Annotation=A combination of EGFR:-216G>T and EGFR:R497K polymorphisms was weakly associated with drug response in NCI-60 cell lines.
|Drugs=erlotinib
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA162372816
}}

{{PMID|17956637|OA=1
}} Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study.

{{PMID|19102716|OA=1
}} EGFR-targeted therapies in lung cancer: predictors of response and toxicity.

{{PMID|19190167|OA=1
}} A two-stage case-control study of EGFR polymorphisms and breast cancer risk.

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}